Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov-Dec;136(6):543-550.
doi: 10.1590/1516-3180.2018.0274161118.

Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study

Evrim Kahramanoğlu Aksoy  1 , Hülya Çetinkaya  2 , Berna Savaş  3 , Arzu Ensari  3 , Murat Torgutalp  4 , Cumali Efe  5
Affiliations

Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study

Evrim Kahramanoğlu Aksoy et al. Sao Paulo Med J. 2018 Nov-Dec.

Abstract

Background: Increased angiogenetic activity in inflammatory bowel disease (IBD) has been shown in previous studies. The aim of this study was to evaluate the relationship of serum vascular endothelial growth factor (VEGF) and endostatin levels with clinical features and mucosal expression in patients with ulcerative colitis (UC).

Design and setting: Cross-sectional analytical study conducted in a tertiary-level public hospital.

Methods: Serum VEGF and endostatin levels were determined in 82 individuals: 39 with UC, 28 with irritable bowel syndrome (IBS) and 15 healthy controls (HCs), using enzyme-linked immunosorbent assays (ELISA). VEGF and endostatin expressions were studied using immunohistochemistry (IHC).

Results: Mean serum VEGF and endostatin levels were significantly higher in patients with UC than in patients with IBS and in HCs (511.9 ± 377.5 pg/ml, 305.0 ± 121.42 pg/ml and 36.1 ± 40.6 pg/ml; P = 0.001 for VEGF; and 155.50 ± 59.8 ng/ml, 116.9 ± 23.8 ng/ml and 102.2 ± 22.4 ng/ml; P < 0.001 for endostatin, respectively). There was a positive correlation between serum VEGF and endostatin levels (r = 0.422; P < 0.01). Mean H-scores for VEGF expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma, endothelium and epithelium. Mean H-scores for endostatin expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma and endothelium. There was no endostatin expression in the epithelium.

Conclusion: Increased endostatin appears to be a defensive reaction to increased VEGF in patients with UC.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None

Figures

Figure 1.
Figure 1.. Flowchart of the study.
Figure 2.
Figure 2.. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and endostatin in the colonic mucosa of ulcerative colitis patients. A: endothelial endostatin expression, x 400; B: stromal endostatin expression, x 400; C: stromal and epithelial VEGF expression, x 400; D: endothelial VEGF expression, x 400.
Figure 3.
Figure 3.. Serum vascular endothelial growth factor (VEGF) levels of the groups.
Figure 4.
Figure 4.. Serum endostatin levels of the groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–429. doi: 10.1056/NEJMra020831. - DOI - PubMed
    1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153–1155. doi: 10.1016/S0092-8674(00)81810-3. - DOI - PubMed
    1. Chidlow JH, Jr, Langston W, Greer JJ. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169(6):2014–2030. doi: 10.2353/ajpath.2006.051021. - DOI - PMC - PubMed
    1. Chidlow JH, Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G5–G18. doi: 10.1152/ajpgi.00107.2007. - DOI - PubMed
    1. Kapsoritakis A, Sfiridaki A, Maltezos E. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18(5):418–422. doi: 10.1007/s00384-003-0495-y. - DOI - PubMed

Substances